SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. announced today that they have selected a second clinical candidate, PPI-1301, from their hepatitis C virus (HCV) NS5A program for advancement into clinical development. Presidio’s first NS5A inhibitor, PPI-461, is currently undergoing evaluation in a Phase 1a clinical study.
